FDA Approves ACYCLOVIR — Advagen Pharma Limited

Advagen Pharma Limited received FDA approval on August 18, 2022, for the Abbreviated New Drug Application ANDA215724, finalizing its launch of the oral acyclovir generic. This action enhances generic competition in the acyclovir market, disrupting the pricing landscape established by subsequent patent exclusivity cliffs.